Cardiovascular Disease

Driving Innovation in Cardiovascular Disease Drug Discovery

Back to Pharmacology and Toxicology Assessment top page

Advancing Cardiovascular Disease Therapeutic Strategies and Drug Discovery

Cardiovascular disease is the leading cause of death in the United States and remains one of the most expensive health conditions, placing a significant burden on the healthcare system. Despite advances in treatment and the availability of existing drugs, innovative drug development remains essential to address the growing burden of cardiovascular disease and improve patient outcomes worldwide.

As a cardiovascular disease preclinical research organization, we take an integrative, whole-animal systems approach to drug discovery. Our unmatched selection of in vivo models for cardiovascular disease and preclinical research services can support cardiovascular drug development at every stage, helping to evaluate and enhance therapeutic efficacy.

Comprehensive Animal Models for Cardiovascular Disease

We offer a full suite of preclinical in vivo models spanning cardiovascular, renal, hepatic, and metabolic diseases, designed with high clinical relevance using surgical, chemical, genetic methods, or a combination of approaches for disease induction. Additionally, we can develop and customize models to meet specific client needs, ensuring tailored solutions for unique research goals. This comprehensive offering enables clients to evaluate therapeutic candidates in realistic, translational models of disease progression.

Explore Our In Vivo Models for Cardiovascular and Related Diseases

Heart
Failure Heart
Failure Inotiv provides translational rodent and large animal models, along with flexible research services and expert consultation, to accelerate heart failure drug discovery. Our in vivo pharmacology services deliver clinically relevant insights and robust efficacy data.

Hypertension and Vascular Disease Hypertension and Vascular Disease Inotiv supports drug discovery with in vivo models of hypertension and vascular disease that enable assessment of cardiac function, target identification, and compound efficacy. Our scientists design tailored studies and ensure comprehensive, goal-aligned testing.

Metabolic
Disease Metabolic
Disease Inotiv supports diabetes, obesity, and metabolic disease research with in vivo models and tailored pharmacology studies. Our translational models deliver clinically relevant insights, with expert guidance from study design to data interpretation to advance therapeutic development.

Pulmonary
Disease Pulmonary
Disease Inotiv provides in vivo models and pharmacology services to support pulmonary disease drug discovery. Our models reflect key features of obstructive, restrictive, and vascular conditions, enabling precise efficacy and safety assessment through customized, expert-guided studies.

Renal
Disease Renal
Disease Inotiv offers a diverse portfolio of rodent models of kidney disease and preclinical research services that support drug discovery efforts with clinically relevant and customizable solutions.

Hepatic
Disease Hepatic
Disease Inotiv supports liver disease research with translational models and comprehensive ex vivo and in vivo services. We offer expert guidance and customizable studies to evaluate efficacy, safety, and mechanisms—advancing drug discovery with meaningful, clinically relevant results.